Usefulness of US Cost-of-Illness Studies in Healthcare Decision Making

By Bloom B.S.   Bruno D.J.   Maman D.Y.   Jayadevappa R.  

PharmacoEconomics, Vol. 19, Iss. 2, 2001-01 ,pp. : 207-213

Adis International

Access to resources Recommend Favorite

Healthcare Rationing by Proxy: Cost-Effectiveness Analysis and the Misuse of the $50 000 Threshold in the US

By Bridges John F.P.  

PharmacoEconomics, Vol. 28, Iss. 3, 2010-03 ,pp. : 175-184

Adis International

Access to resources Recommend Favorite

US big spender on healthcare

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 365, 2002-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients: US Healthcare System Perspective

By Delea Thomas E.  

PharmacoEconomics, Vol. 25, Iss. 4, 2007-01 ,pp. : 329-342

Adis International

Access to resources Recommend Favorite

DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA

By Lesko Lawrence J   Zineh Issam  

Pharmacogenomics, Vol. 11, Iss. 4, 2010-04 ,pp. : 507-512

Future Medicine

Access to resources Recommend Favorite